Literature DB >> 1335431

Prognostic significance of polymerase chain reaction detected human papillomavirus of tumors and lymph nodes in surgically treated stage IB cervical cancer.

A F Burnett1, W A Barnes, J C Johnson, E Grendys, G D Willett, J F Barter, J Doniger.   

Abstract

This study describes the prognostic role of polymerase chain reaction detected human papillomavirus (HPV) in Stage IB cervical cancer patients treated with radical hysterectomy and pelvic and paraaortic node dissection. All tumors were confined to the cervix and all margins and nodes were disease free. Twenty-one patients were analyzed: 6 patients recurred within 20 months of initial therapy, while 15 had no evidence of disease with a minimum follow-up of 36 months. Polymerase chain reaction (PCR) was performed on paraffin-block tissue of the hysterectomy specimen cervical tumor and lymph nodes. Oligonucleotide probes for HPV types 6, 11, 16, 18, 31, 33, and 35 were used with consensus primers for uncharacterized HPV types created from an L1 constant region. Control tissues were run with each tumor sample to assure against contamination. HPV type confirmation was performed using diagnostic restriction sites. HPV was detected in all cervical tumors. Recurring tumors were infected with multiple types of HPV in all 6 tumors versus only 5 of 15 nonrecurring tumors being multiply infected (P = 0.023). No tumor had HPV 6 or 11, and the incidence of HPV 16, 31, 33, and 35 was not significantly different for recurrent versus nonrecurrent groups. HPV 18 was found in 5 of 6 recurring cancers versus 1 of 15 nonrecurring tumors (P = 0.0029). PCR typing of the histologically negative nodes that had been obtained at radical hysterectomy was done in all 6 recurring patients and in 6 nonrecurring patients. The recurrent patients had a significantly higher incidence of lymph nodes positive for HPV DNA (71%) than the nonrecurring patients (35%) (P = 0.0047). These observations suggest that HPV 18 cervical cancer patients, those with infections of multiple types, and those with HPV DNA in histologically negative lymph nodes may be at increased risk for recurrence.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335431     DOI: 10.1016/0090-8258(92)90137-8

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas.

Authors:  M F Baay; W G Quint; J Koudstaal; H Hollema; J M Duk; M P Burger; E Stolz; P Herbrink
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

2.  Detection of HPV-16 DNA by PCR in histologically cancer free lymph nodes from patients with cervical cancer.

Authors:  M F Baay; J Koudstaal; H Hollema; J M Duk; M P Burger; W G Quint; E Stolz; P Herbrink
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

Review 3.  Usefulness, methods and rationale of lymph nodes HPV-DNA investigation in estimating risk of early stage cervical cancer recurrence: a systematic literature review.

Authors:  Marco Noventa; Emanuele Ancona; Erich Cosmi; Carlo Saccardi; Pietro Litta; Donato D'Antona; Giovanni Battista Nardelli; Salvatore Gizzo
Journal:  Clin Exp Metastasis       Date:  2014-07-20       Impact factor: 5.150

Review 4.  Importance of investigating high-risk human papillomavirus in lymph node metastasis of esophageal adenocarcinoma.

Authors:  Preeti Sharma; Shweta Dutta Gautam; Shanmugarajah Rajendra
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

5.  [Effect of EGFR-TKI on lymphangiogenesis of lung cancer with EGFR mutation].

Authors:  Minghui Cai; Xinying Yang; Baohong Jiang; Fukang Teng; Yan Pan; Feng Mao; Yang Shen-Tu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-12

6.  Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination.

Authors:  Jeremy D Goldhaber-Fiebert; Natasha K Stout; Jesse Ortendahl; Karen M Kuntz; Sue J Goldie; Joshua A Salomon
Journal:  Popul Health Metr       Date:  2007-10-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.